OPB-111077 belongs to a novel class of inhibitors that affect both the nuclear and mitochondrial function of STAT3 [37], and recent clinical trials have tested it as a single agent in HCC patients [38,39]. Here, STAT3 is linked to hepatocellular carcinoma.